Cancer Immunotherapy
Creative Biolabs Launches Integrated Cell Therapy Platforms to Advance Cancer Immunotherapy
Creative Biolabs has launched fully integrated CAR-T and TIL therapy development platforms, providing researchers and biotech startups with comprehensive services to accelerate the development of next-generation cellular immunotherapies for cancer treatment.
Kairos Pharma Ltd. Showcases Promising Preclinical Results for KROS101 at ASCO 2025
Kairos Pharma Ltd. reveals preclinical data at ASCO 2025 indicating KROS101's potential to enhance cancer immunotherapy by improving T cell activity and reducing immune suppression.
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700
Tonix Pharmaceuticals presented positive preclinical results for TNX-1700, a fusion protein showing potential in reducing immunosuppressive cells and enhancing anti-tumor immune responses in gastric cancer models, particularly when combined with anti-PD1 therapy.
BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
BriaCell Therapeutics has completed a public offering of 3,066,666 units, generating approximately $13.8 million to support its clinical-stage cancer immunotherapy development efforts. The funding will help the company advance its research and corporate objectives.
Creative Biolabs Advances CIK Cell Therapy Development for Cancer Treatment
Creative Biolabs offers comprehensive solutions for cytokine-induced killer (CIK) cell therapy development, potentially accelerating cancer immunotherapy research through advanced cellular isolation, expansion, and characterization techniques.